CHD7 Expression Predicts Survival Outcomes in Patients with Resected Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with poor outcomes with current therapies. Gemcitabine is the primary adjuvant drug used clinically, but its effectiveness is limited. In this study, our objective was to utilize a rationale-driven approach to identify novel biomarkers...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Colbert, Lauren E., Petrova, Aleksandra V., Fisher, Sarah B., Pantazides, Brooke G., Madden, Matthew Z., Hardy, Claire W., Warren, Matthew D., Pan, Yunfeng, Nagaraju, Ganji P., Liu, Elaine A., Saka, Burcu, Hall, William A., Shelton, Joseph W., Gandhi, Khanjan, Pauly, Rini, Kowalski, Jeanne, Kooby, David A., El-Rayes, Bassel F., Staley, Charles A., Adsay, N. Volkan, Curran, Walter J., Landry, Jerome C., Maithel, Shishir K., Yu, David S.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2014
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4025946/
https://ncbi.nlm.nih.gov/pubmed/24626090
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-13-1996
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi